Hepatocellular carcinoma and the ubiquitin-proteasome system

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1782, Issue 12, 2008, Pages 775-784

  Dawson, Simon P ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cancer; Hepatocellular carcinoma; Inflammation; Proteasome; Ubiquitin

Indexed keywords

FAT10 PROTEIN; GANKYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARKIN; PROTEASOME; PROTEIN DERIVATIVE; RING FINGER PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CROSS LINKING; DISEASE COURSE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MORTALITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 56449125383     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.08.003     Document Type: Review

References (153)

1. Okuda K. Hepatocellular carcinoma. J. Hepatol. 32 (2000) 225-237
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
3. Bosch F.X., Ribes J., and Borras J. Epidemiology of primary liver cancer. Semin. Liver Dis. 19 (1999) 271-285
4. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
5. Kew M.C. Epidemiology of hepatocellular carcinoma. Toxicology 181-182 (2002) 35-38
6. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide vol. 5 (2004), International Agency for Research on Cancer, Lyon
7. Coleman M.P., Gatta G., Verdecchia A., Esteve J., Sant M., Storm H., Allemani C., Ciccolallo L., Santaquilani M., and Berrino F. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann. Oncol. 14 Suppl 5 (2003) v128-149
8. Ries L.A.G., Melbert D., Krapcho M., Stinchcomb D.G., Howlader N., Horner M.J., Mariotto A., Miller B.A., Feuer E.J., Altekruse S.F., Lewis D.R., Clegg L., Eisner M.P., Reichman M., and Edwards B.K. SEER Cancer Statistics Review 1975-2005 (2008), National Cancer Institute, Bethesda, MD
9. Benhamiche A.M., Faivre C., Minello A., Clinard F., Mitry E., Hillon P., and Faivre J. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J. Hepatol. 29 (1998) 802-806
10. McGlynn K.A., Tsao L., Hsing A.W., Devesa S.S., and Fraumeni Jr. J.F. International trends and patterns of primary liver cancer. Int. J. Cancer 94 (2001) 290-296
11. Okuda K., Fujimoto I., Hanai A., and Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 47 (1987) 4967-4972
12. Taylor-Robinson S.D., Foster G.R., Arora S., Hargreaves S., and Thomas H.C. Increase in primary liver cancer in the UK, 1979-94. Lancet 350 (1997) 1142-1143
13. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 62 Suppl 1 (2002) 8-17
14. Frank C., Mohamed M.K., Strickland G.T., Lavanchy D., Arthur R.R., Magder L.S., El Khoby T., Abdel-Wahab Y., Aly Ohn E.S., Anwar W., and Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 (2000) 887-891
15. Di Bisceglie A.M., Carithers Jr. R.L., and Gores G.J. Hepatocellular carcinoma. Hepatology 28 (1998) 1161-1165
16. McKillop I.H., Moran D.M., Jin X., and Koniaris L.G. Molecular pathogenesis of hepatocellular carcinoma. J. Surg. Res. 136 (2006) 125-135
17. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
18. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
19. Maeda S., Kamata H., Luo J.L., Leffert H., and Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
20. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., Roskams T., Trautwein C., and Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11 (2007) 119-132
21. Hayden M.S., and Ghosh S. Signaling to NF-kappaB. Genes Dev. 18 (2004) 2195-2224
22. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8 (2007) 49-62
23. Arsura M., and Cavin L.G. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 229 (2005) 157-169
24. Luedde T., and Trautwein C. Intracellular survival pathways in the liver. Liver Int. 26 (2006) 1163-1174
25. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., and Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334 (1996) 693-699
26. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 134 (2008) 379
27. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., and Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66 (2006) 11851-11858
28. Simpson D., and Keating G.M. Sorafenib: in hepatocellular carcinoma. Drugs 68 (2008) 251-258
29. Hopfner M., Sutter A.P., Huether A., Schuppan D., Zeitz M., and Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J. Hepatol. 41 (2004) 1008-1016
30. Philip P.A., Mahoney M.R., Allmer C., Thomas J., Pitot H.C., Kim G., Donehower R.C., Fitch T., Picus J., and Erlichman C. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23 (2005) 6657-6663
31. Zhu A.X., Blaszkowsky L.S., Ryan D.P., Clark J.W., Muzikansky A., Horgan K., Sheehan S., Hale K.E., Enzinger P.C., Bhargava P., and Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24 (2006) 1898-1903
32. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., and Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336 (1997) 1855-1859
33. Ikeda K., Saitoh S., Arase Y., Chayama K., Suzuki Y., Kobayashi M., Tsubota A., Nakamura I., Murashima N., Kumada H., and Kawanishi M. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29 (1999) 1124-1130
34. Reichard O., Schvarcz R., and Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 26 (1997) 108S-111S
35. Kerscher O., Felberbaum R., and Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22 (2006) 159-180
36. Pickart C.M., and Cohen R.E. Proteasomes and their kin: proteases in the machine age. Nat. Rev. Mol. Cell Biol. 5 (2004) 177-187
37. Pickart C.M., and Eddins M.J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695 (2004) 55-72
38. Roos-Mattjus P., and Sistonen L. The ubiquitin-proteasome pathway. Ann. Med. 36 (2004) 285-295
39. Nandi D., Tahiliani P., Kumar A., and Chandu D. The ubiquitin-proteasome system. J. Biosci. 31 (2006) 137-155
40. Welchman R.L., Gordon C., and Mayer R.J. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev. Mol. Cell Biol. 6 (2005) 599-609
41. Reed S.I. The ubiquitin-proteasome pathway in cell cycle control. Results Probl. Cell Differ. 42 (2006) 147-181
42. Chen D., Kon N., Li M., Zhang W., Qin J., and Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121 (2005) 1071-1083
43. Liu C.H., Goldberg A.L., and Qiu X.B. New insights into the role of the ubiquitin-proteasome pathway in the regulation of apoptosis. Chang Gung Med. J. 30 (2007) 469-479
44. Yang Y., and Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J. 17 (2003) 790-799
45. Zhong Q., Gao W., Du F., and Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121 (2005) 1085-1095
46. Shenoy S.K. Seven-transmembrane receptors and ubiquitination. Circ. Res. 100 (2007) 1142-1154
47. Terzic J., Marinovic-Terzic I., Ikeda F., and Dikic I. Ubiquitin signals in the NF-kappaB pathway. Biochem. Soc. Trans. 35 (2007) 942-945
48. Chauhan D., Hideshima T., and Anderson K.C. Targeting proteasomes as therapy in multiple myeloma. Adv. Exp. Med. Biol. 615 (2008) 251-260
49. Krzywda S., Brzozowski A.M., Higashitsuji H., Fujita J., Welchman R., Dawson S., Mayer R.J., and Wilkinson A.J. The crystal structure of gankyrin, an oncoprotein found in complexes with CDK4, a 19S proteasomal ATPase regulator and the tumour suppressors Rb and p53. J. Biol. Chem. 279 (2004) 1541-1545
50. Hori T., Kato S., Saeki M., DeMartino G.N., Slaughter C.A., Takeuchi J., and Tohe A. K. Tanaka, cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome. Gene 216 (1998) 113-122
51. Dawson S., Apcher S., Mee M., Higashitsuji H., Baker R., Uhle S., Dubiel W., Fujita J., and Mayer J. Gankyrin: an ankyrin-repeat oncoprotein interacts with CDK4 kinase and the S6 ATPase of the 26S proteasome. J. Biol. Chem. 277 (2002) 10893-10902
52. Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T., Mayer R.J., Arii S., and Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 6 (2000) 96-99
53. Lim I.K. Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fisher 344 male rats. Mech. Ageing Dev. 124 (2003) 697-708
54. Fu X.Y., Wang H.Y., Tan L., Liu S.Q., Cao H.F., and Wu M.C. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J. Gastroenterol. 8 (2002) 638-643
55. Li H., Fu X., Chen Y., Hong Y., Tan Y., Cao H., Wu M., and Wang H. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 128 (2005) 2029-2041
56. Higashitsuji H., Itoh K., Sakurai T., Nagao T., Sumitomo H., Masuda T., Dawson S., Shimada Y., Mayer R.J., and Fujita J. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 8 (2005) 75-87
57. Shan Y.F., Zhou W.P., Fu X.Y., Yan H.X., Yang W., Liu S.Q., Cao H.F., Kang B., Wu M.C., and Wang H.Y. The role of p28GANK in rat oval cells activation and proliferation. Liver Int. 26 (2006) 240-247
58. Dick F.A., Sailhamer E., and Dyson N.J. Mutagenesis of the pRB pocket reveals that cell cycle arrest functions are separable from binding to viral oncoproteins. Mol. Cell Biol. 20 (2000) 3715-3727
59. Li J., and Tsai M.D. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry 41 (2002) 3977-3983
60. Nakamura Y., Nakano K., Umehara T., Kimura M., Hayashizaki Y., Tanaka A., Horikoshi M., Padmanabhan B., and Yokoyama S. Structure of the oncoprotein gankyrin in complex with S6 ATPase of the 26S proteasome. Structure 15 (2007) 179-189
61. Mahajan A., Guo Y., Yuan C., Weghorst C.M., Tsai M.D., and Li J. Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16. J. Mol. Biol. 373 (2007) 990-1005
62. Azechi H., Nishida N., Fukuda Y., Nishimura T., Minata M., Katsuma H., Kuno M., Ito T., Komeda T., Kita R., Takahashi R., and Nakao K. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 60 (2001) 346-354
63. Chen Y., Sharp Z.D., and Lee W.H. HEC binds to the seventh regulatory subunit of the 26 S proteasome and modulates the proteolysis of mitotic cyclins. J. Biol. Chem. 272 (1997) 24081-24087
64. Ueda H., Ullrich S.J., Gangemi J.D., Kappel C.A., Ngo L., Feitelson M.A., and Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 9 (1995) 41-47
65. Joazeiro C.A., and Weissman A.M. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102 (2000) 549-552
66. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
67. Kubbutat M.H.G., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
68. Qiu W., Wu J., Walsh E.M., Zhang Y., Chen C.Y., Fujita J., and Xiao Z.X. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells. Oncogene 27 (2008) 4034-4043
69. Chen Y., Li H.H., Fu J., Wang X.F., Ren Y.B., Dong L.W., Tang S.H., Liu S.Q., Wu M.C., and Wang H.Y. Oncoprotein p28 GANK binds to RelA and retains NF-kappaB in the cytoplasm through nuclear export. Cell Res. 17 (2007) 1020-1029
70. Higashitsuji H., Liu Y., Masuda T., Fujita T., Abdel-Aziz H.I., Kongkham S., Dawson S., John Mayer R., Itoh Y., Sakurai T., Itoh K., and Fujita J. The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity. Biochem. Biophys. Res. Commun. 363 (2007) 879-884
71. Aufiero B., and Schneider R.J. The hepatitis B virus X-gene product trans-activates both RNA polymerase II and III promoters. EMBO J. 9 (1990) 497-504
72. Zoulim F., Saputelli J., and Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol. 68 (1994) 2026-2030
73. Hu Z.Y., Zhang Z.S., Doo E., Coux O., Goldberg A.L., and Liang T.J. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J. Virol. 73 (1999) 7231-7240
74. Sirma H., Weil R., Rosmorduc O., Urban S., Israel A., Kremsdorf D., and Brechot C. Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene 16 (1998) 2051-2063
75. Zhang Z., Protzer U., Hu Z., Jacob J., and Liang T.J. Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner. J. Virol. 78 (2004) 4566-4572
76. Loureiro J., and Ploegh H.L. Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv. Immunol. 92 (2006) 225-305
77. Stohwasser R., Holzhutter H.G., Lehmann U., Henklein P., and Kloetzel P.M. Hepatitis B virus HBx peptide 116-138 and proteasome activator PA28 compete for binding to the proteasome alpha4/MC6 subunit. Biol. Chem. 384 (2003) 39-49
78. Kloetzel P.M. The proteasome and MHC class I antigen processing. Biochim. Biophys. Acta 1695 (2004) 225-233
79. Kalra N., and Kumar V. The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc. FEBS Lett. 580 (2006) 431-436
80. Jung J.K., Kwun H.J., Lee J.O., Arora P., and Jang K.L. Hepatitis B virus X protein differentially affects the ubiquitin-mediated proteasomal degradation of beta-catenin depending on the status of cellular p53. J. Gen. Virol. 88 (2007) 2144-2154
81. Bontron S., Lin-Marq N., and Strubin M. Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2. J. Biol. Chem. 277 (2002) 38847-38854
82. Leupin O., Bontron S., and Strubin M. Hepatitis B virus X protein and simian virus 5 V protein exhibit similar UV-DDB1 binding properties to mediate distinct activities. J. Virol. 77 (2003) 6274-6283
83. Lee J., and Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol. Cell 26 (2007) 775-780
84. O'Connell B.C., and Harper J.W. Ubiquitin proteasome system (UPS): what can chromatin do for you?. Curr. Opin. Cell Biol. 19 (2007) 206-214
85. Sitterlin D., Bergametti F., Tiollais P., Tennant B.C., and Transy C. Correct binding of viral X protein to UVDDB-p127 cellular protein is critical for efficient infection by hepatitis B viruses. Oncogene 19 (2000) 4427-4431
86. Le Rouzic E., Belaidouni N., Estrabaud E., Morel M., Rain J.C., Transy C., and Margottin-Goguet F. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6 (2007) 182-188
87. Le Rouzic E., Morel M., Ayinde D., Belaidouni N., Letienne J., Transy C., and Margottin-Goguet F. Assembly with the Cul4A-DDB1DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation. J. Biol. Chem. 283 (2008) 21686-21692
88. Li T., Chen X., Garbutt K.C., Zhou P., and Zheng N. Structure of DDB1 in complex with a paramyxovirus V protein: viral hijack of a propeller cluster in ubiquitin ligase. Cell 124 (2006) 105-117
89. Petroski M.D., and Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6 (2005) 9-20
90. Berndt C., Bech-Otschir D., Dubiel W., and Seeger M. Ubiquitin system: JAMMing in the name of the lid. Curr. Biol. 12 (2002) R815-817
91. Wee S., Geyer R.K., Toda T., and Wolf D.A. CSN facilitates Cullin-RING ubiquitin ligase function by counteracting autocatalytic adapter instability. Nat. Cell Biol. 7 (2005) 387-391
92. Zhou C., Wee S., Rhee E., Naumann M., Dubiel W., and Wolf D.A. Fission yeast COP9/signalosome suppresses cullin activity through recruitment of the deubiquitylating enzyme Ubp12p. Mol. Cell 11 (2003) 927-938
93. Patil M.A., Gutgemann I., Zhang J., Ho C., Cheung S.T., Ginzinger D., Li R., Dykema K.J., So S., Fan S.T., Kakar S., Furge K.A., Buttner R., and Chen X. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis 26 (2005) 2050-2057
94. Munakata T., Nakamura M., Liang Y., Li K., and Lemon S.M. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. USA 102 (2005) 18159-18164
95. Munakata T., Liang Y., Kim S., McGivern D.R., Huibregtse J., Nomoto A., and Lemon S.M. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog. 3 (2007) 1335-1347
96. Huibregtse J.M., Scheffner M., and Howley P.M. Cloning and expression of the cDNA for E6-Ap, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with P53. Mol. Cell Biol. 13 (1993) 775-784
97. Nemani M., Linares-Cruz G., Bruzzoni-Giovanelli H., Roperch J.P., Tuynder M., Bougueleret L., Cherif D., Medhioub M., Pasturaud P., Alvaro V., der Sarkissan H., Cazes L., Le Paslier D., Le Gall I., Israeli D., Dausset J., Sigaux F., Chumakov I., Oren M., Calvo F., Amson R.B., Cohen D., and Telerman A. Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Proc. Natl. Acad. Sci. USA 93 (1996) 9039-9042
98. Liu J., Stevens J., Rote C.A., Yost H.J., Hu Y., Neufeld K.L., White R.L., and Matsunami N. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 7 (2001) 927-936
99. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., and Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27 (2007) 55-76
100. Matsuo K., Satoh S., Okabe H., Nomura A., Maeda T., Yamaoka Y., and Ikai I. SIAH1 inactivation correlates with tumor progression in hepatocellular carcinomas. Genes. Chromosomes Cancer 36 (2003) 283-291
101. Marin I., Lucas J.I., Gradilla A.C., and Ferrus A. Parkin and relatives: the RBR family of ubiquitin ligases. Physiol. Genomics 17 (2004) 253-263
102. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7 (2006) 306-318
103. Denison S.R., Wang F., Becker N.A., Schule B., Kock N., Phillips L.A., Klein C., and Smith D.I. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22 (2003) 8370-8378
104. Cesari R., Martin E.S., Calin G.A., Pentimalli F., Bichi R., McAdams H., Trapasso F., Drusco A., Shimizu M., Masciullo V., D'Andrilli G., Scambia G., Picchio M.C., Alder H., Godwin A.K., and Croce C.M. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc. Natl. Acad. Sci. USA 100 (2003) 5956-5961
105. Wang F., Denison S., Lai J.P., Philips L.A., Montoya D., Kock N., Schule B., Klein C., Shridhar V., Roberts L.R., and Smith D.I. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40 (2004) 85-96
106. M. Fujiwara, H. Marusawa, H.Q. Wang, A. Iwai, K. Ikeuchi, Y. Imai, A. Kataoka, N. Nukina, R. Takahashi, T. Chiba, Parkin as a tumor suppressor gene for hepatocellular carcinoma, Oncogene (in press).
107. Agirre X., Roman-Gomez J., Vazquez I., Jimenez-Velasco A., Garate L., Montiel-Duarte C., Artieda P., Cordeu L., Lahortiga I., Calasanz M.J., Heiniger A., Torres A., Minna J.D., and Prosper F. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int. J. Cancer 118 (2006) 1945-1953
108. Bonizzi G., and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25 (2004) 280-288
109. Chen Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7 (2005) 758-765
110. Hellerbrand C., Bumes E., Bataille F., Dietmaier W., Massoumi R., and Bosserhoff A.K. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28 (2007) 21-27
111. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., Fan S.T., Luk J.M., Wigler M., Hannon G.J., Mu D., Lucito R., Powers S., and Lowe S.W. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006) 1253-1267
112. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J., Flygare J.A., Fairbrother W.J., Deshayes K., Dixit V.M., and Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131 (2007) 669-681
113. Varfolomeev E., and Vucic D. (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 7 (2008) 1511-1521
114. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos C.A., Chunduru S.K., Condon S.M., McKinlay M., Brink R., Leverkus M., Tergaonkar V., Schneider P., Callus B.A., Koentgen F., Vaux D.L., and Silke J. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131 (2007) 682-693
115. Kaur S., Wang F., Venkatraman M., and Arsura M. X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). J. Biol. Chem. 280 (2005) 38599-38608
116. Brummelkamp T.R., Nijman S.M., Dirac A.M., and Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424 (2003) 797-801
117. Kovalenko A., Chable-Bessia C., Cantarella G., Israel A., Wallach D., and Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424 (2003) 801-805
118. Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., and Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125 (2006) 665-677
119. Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., and Siebenlist U. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72 (1993) 729-739
120. Fujita T., Nolan G.P., Liou H.C., Scott M.L., and Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 7 (1993) 1354-1363
121. Nolan G.P., Fujita T., Bhatia K., Huppi C., Liou H.C., Scott M.L., and Baltimore D. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol. Cell Biol. 13 (1993) 3557-3566
122. Franzoso G., Carlson L., Scharton-Kersten T., Shores E.W., Epstein S., Grinberg A., Tran T., Shacter E., Leonardi A., Anver M., Love P., Sher A., and Siebenlist U. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 6 (1997) 479-490
123. Schwarz E.M., Krimpenfort P., Berns A., and Verma I.M. Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev. 11 (1997) 187-197
124. Simonson S.J., Wu Z.H., and Miyamoto S. CYLD: a DUB with many talents. Dev. Cell 13 (2007) 601-603
125. Sun S.C. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 8 (2008) 501-511
126. Hunter A.M., LaCasse E.C., and Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12 (2007) 1543-1568
127. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., and Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17 (1998) 2215-2223
128. Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388 (1997) 300-304
129. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16 (1997) 6914-6925
130. Li X., Yang Y., and Ashwell J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416 (2002) 345-347
131. Samuel T., Welsh K., Lober T., Togo S.H., Zapata J.M., and Reed J.C. Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. J. Biol. Chem. 281 (2006) 1080-1090
132. Park S.M., Yoon J.B., and Lee T.H. Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett. 566 (2004) 151-156
133. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., Dave S., Hurt E.M., Tan B., Zhao H., Stephens O., Santra M., Williams D.R., Dang L., Barlogie B., Shaughnessy Jr. J.D., Kuehl W.M., and Staudt L.M. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12 (2007) 115-130
134. Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.J., Van Wier S., Tiedemann R., Shi C.X., Sebag M., Braggio E., Henry T., Zhu Y.X., Fogle H., Price-Troska T., Ahmann G., Mancini C., Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M., Valdez R., Trent J., Stewart A.K., Carpten J., and Bergsagel P.L. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12 (2007) 131-144
135. Chai J., Du C., Wu J.W., Kyin S., Wang X., and Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406 (2000) 855-862
136. Hegde R., Srinivasula S.M., Zhang Z., Wassell R., Mukattash R., Cilenti L., DuBois G., Lazebnik Y., Zervos A.S., Fernandes-Alnemri T., and Alnemri E.S. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem. 277 (2002) 432-438
137. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J., Lee R.A., Robbins P.D., Fernandes-Alnemri T., Shi Y., and Alnemri E.S. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410 (2001) 112-116
138. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
139. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., and Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 (2000) 43-53
140. Wu G., Chai J., Suber T.L., Wu J.W., Du C., Wang X., and Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 408 (2000) 1008-1012
141. Liu Z., Sun C., Olejniczak E.T., Meadows R.P., Betz S.F., Oost T., Herrmann J., Wu J.C., and Fesik S.W. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408 (2000) 1004-1008
142. Nakano H., Nakajima A., Sakon-Komazawa S., Piao J.H., Xue X., and Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 13 (2006) 730-737
143. Papa S., Bubici C., Zazzeroni F., Pham C.G., Kuntzen C., Knabb J.R., Dean K., and Franzoso G. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 13 (2006) 712-729
144. Fan W., Cai W., Parimoo S., Schwarz D.C., Lennon G.G., and Weissman S.M. Identification of seven new human MHC class I region genes around the HLA-F locus. Immunogenetics 44 (1996) 97-103
145. Raasi S., Schmidtke G., de Giuli R., and Groettrup M. A ubiquitin-like protein which is synergistically inducible by interferon-gamma and tumor necrosis factor-alpha. Eur. J. Immunol. 29 (1999) 4030-4036
146. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70 (2001) 503-533
147. Raasi S., Schmidtke G., and Groettrup M. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J. Biol. Chem. 276 (2001) 35334-35343
148. Lee C.G., Ren J., Cheong I.S., Ban K.H., Ooi L.L., Yong Tan S., Kan A., Nuchprayoon I., Jin R., Lee K.H., Choti M., and Lee L.A. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 22 (2003) 2592-2603
149. Oliva J., Bardag-Gorce F., French B.A., Li J., McPhaul L., Amidi F., Dedes J., Habibi A., Nguyen S., and French S.W. Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. Exp. Mol. Pathol. 84 (2008) 102-112
150. S. Lukasiak, C. Schiller, P. Oehlschlaeger, G. Schmidtke, P. Krause, D.F. Legler, F. Autschbach, P. Schirmacher, K. Breuhahn, M. Groettrup, Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon, Oncogene (in press).
151. Bardag-Gorce F., Dedes J., French B.A., Oliva J.V., Li J., and French S.W. Mallory body formation is associated with epigenetic phenotypic change in hepatocytes in vivo. Exp. Mol. Pathol. 83 (2007) 160-168
152. Nan L., Bardag-Gorce F., Wu Y., Li J., French B.A., and French S.W. Mallory body forming cells express the preneoplastic hepatocyte phenotype. Exp. Mol. Pathol. 80 (2006) 109-118
153. Roomi M.W., Gaal K., Yuan Q.X., French B.A., Fu P., Bardag-Gorce F., and French S.W. Preneoplastic liver cell foci expansion induced by thioacetamide toxicity in drug-primed mice. Exp. Mol. Pathol. 81 (2006) 8-14